Imaging and dosimetry for radium-223: the potential for personalized treatment.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

29 citing papers in PubMed.

1. Evaluation of Safety and Dosimetry ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021
   Trial
2. Pharmacodynamic study of radium-223 in men with bone metastatic castration resistant prostate cancer.PloS one · 2019
   Trial
3. Impact of simulation settings, time-activity curve integration range, and imaging time points on full Monte Carlo-basedAnnals of nuclear medicine · 2026
   Article
4. Towards practical radiopharmaceutical treatment planning: a review of dosimetry simplification techniques.Theranostics · 2026
   Review
5. Clinical application of targeted α-emitter therapy in gastroenteropancreatic neuroendocrine neoplasms.Journal of gastroenterology · 2025
   Review
6. Establishment of a practical methodology for evaluating equieffective dose of individual patients based on RT-PHITS.EJNMMI physics · 2025
   Article
7. The Tight Relationship Between the Tumoral Microenvironment and Radium-223.Biomedicines · 2025
   Review
8. Biodistribution and dosimetry ofEJNMMI research · 2024
   Article
9. Radiometals in Imaging and Therapy: Highlighting Two Decades of Research.Pharmaceuticals (Basel, Switzerland) · 2023
   Review
10. Heterogeneity of dose distribution in normal tissues in case of radiopharmaceutical therapy with alpha-emitting radionuclides.Radiation and environmental biophysics · 2022
    Review
11. Biological and Clinical Aspects of Metastatic Spinal Tumors.Cancers · 2022
    Review
12. Ionizing Radiation from Radiopharmaceuticals and the Human Gut Microbiota: An Ex Vivo Approach.International journal of molecular sciences · 2022
    Article
13. Prospective testing of clinical Cerenkov luminescence imaging against standard-of-care nuclear imaging for tumour location.Nature biomedical engineering · 2022
    Observational
14. Opportunistic skeletal muscle metrics as prognostic tools in metastatic castration-resistant prostate cancer patients candidates to receive Radium-223.Annals of nuclear medicine · 2022
    Article
15. Radium-223 as an Additional Therapeutic Strategy in Highly Selected Patients With Metastatic Breast Cancer: A Case Report.Frontiers in oncology · 2022
    Article
16. Real-world effectiveness, long-term safety and treatment pathway integration of radium-223 therapy in patients with metastatic castration-resistant prostate cancer.Frontiers in medicine · 2022
    Review
17. Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box.European journal of nuclear medicine and molecular imaging · 2021
    Review
18. Radiopharmacokinetic modelling and radiation dose assessment ofEJNMMI physics · 2021
    Article
19. The Role of Theranostics in Prostate Cancer.Seminars in radiation oncology · 2021
    Review
20. Practical considerations for quantitative clinical SPECT/CT imaging of alpha particle emitting radioisotopes.Theranostics · 2021
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

Abstract

Indexed as